Challenges in the Development and Reimbursement of Personalized Medicine—Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research: A Report of the ISPOR Personalized Medicine Special Interest Group

Abstract Background Personalized medicine technologies can improve individual health by delivering the right dose of the right drug to the right patient at the right time but create challenges in deciding which technologies offer sufficient value to justify widespread diffusion. Personalized medicin...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Value in health 2012-12, Vol.15 (8), p.1162-1171
Hauptverfasser:	Faulkner, Eric, MPH, Annemans, Lieven, PhD, MSc, Garrison, Lou, PhD, Helfand, Mark, MD, MPH, Holtorf, Anke-Peggy, PhD, MBA, Hornberger, John, MD, MS, Hughes, Dyfrig, PhD, MRPharmS, Li, Tracy, PhD, Malone, Daniel, PhD, Payne, Katherine, PhD, Siebert, Uwe, MD, MPH, MSc, ScD, Towse, Adrian, MA, Veenstra, David, PhD, PharmD, Watkins, John, PharmD, MPH, BCPS
Format:	Artikel
Sprache:	eng
Schlagworte:	Best practice Biomedical Research diagnostics Drug Industry - economics Drug Industry - organization & administration Economics, Pharmaceutical Health Health economics health economics and outcomes research Health Services Accessibility - economics Health status health technology assessment Humans Individualized Insurance, Health, Reimbursement - statistics & numerical data Internal Medicine Medical research Outcome Assessment (Health Care) - economics Outcome Assessment (Health Care) - methods personalized medicine Pharmacogenetics Precision Medicine - economics Precision Medicine - methods reimbursement Technology Assessment, Biomedical
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!